Pros

Phreesia’s Hilary Hatch Named a “Disrupter” in PM360’s ELITE 100

Retrieved on: 
Tuesday, May 16, 2023
Technology, General Health, Professional Services, Science, Clinical Trials, Health, Health Technology, Health Insurance, Other Science, Research, Other Technology, Telemedicine, Virtual Medicine, Software, Other Health, Other Professional Services, Human Resources, Practice Management, Pros, The New England Journal of Medicine, PAM, Harvard University, Policy, COVID-19, Human, ELITE, SDOH, CMMI, Doctor of Philosophy, Patient Activation Measure, Medicare, Center for Medicare and Medicaid Innovation, Commonwealth Fund, National Quality Forum, Public health, Acquisition, Commonwealth, Patient, Collection, NQF, City University, Pharmaceutical industry, Nursing, Phreesia

Phreesia is pleased to announce that Hilary Hatch, PhD, Phreesia’s Chief Clinical Officer, has been named as one of the 2023 PM360 ELITE 100 by healthcare-marketing trade publication, PM360.

Key Points: 
  • Phreesia is pleased to announce that Hilary Hatch, PhD, Phreesia’s Chief Clinical Officer, has been named as one of the 2023 PM360 ELITE 100 by healthcare-marketing trade publication, PM360.
  • This year’s ELITE 100 were chosen from among 500 submissions across 19 categories.
  • The PM360 ELITE Awards recognize individuals and teams who have made a significant impact on the healthcare industry.
  • Winners are selected by the PM360 editorial staff based on their career accomplishments and the influence they’ve had on the industry.

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

Retrieved on: 
Thursday, May 11, 2023
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Abstract, Pros, European Hematology Association, Multiple myeloma, TCE, American Society of Clinical Oncology, RCT, Spectroscopy, Trial of the century, ASCO, Congress, CAR, Patient, Risk, Randomized controlled trial, Quality of life (healthcare), EHA, Annual general meeting, MM, RRMM, Society, Pharmaceutical industry, Nursing, Idecabtagene vicleucel

The presentations will highlight clinical and correlative data from the KarMMa-2 and KarMMa-3 clinical trials evaluating Abecma (idecabtagene vicleucel) in patients with relapsed and/or refractory multiple myeloma (RRMM) or newly diagnosed multiple myeloma.

Key Points: 
  • The presentations will highlight clinical and correlative data from the KarMMa-2 and KarMMa-3 clinical trials evaluating Abecma (idecabtagene vicleucel) in patients with relapsed and/or refractory multiple myeloma (RRMM) or newly diagnosed multiple myeloma.
  • “These data highlight the growing body of evidence that further support the value of Abecma across various subgroups of patients with triple-class-exposed relapsed and/or refractory multiple myeloma, who, despite recent advancements, still need more effective treatment options sooner,” said Steve Bernstein, M.D., chief medical officer, 2seventy bio.
  • Additional analysis of outcomes by number of prior lines of therapy from the KarMMa-3 clinical trial showcasing the use of Abecma in patients who received two to four prior lines of therapy.
  • Patient-reported outcomes from the pivotal Phase 3 KarMMa-3 trial in patients with triple-class exposed RRMM treated with Abecma versus standard regimens.

Frontdoor Surpasses 225,000 Downloads in First Month!

Retrieved on: 
Wednesday, May 10, 2023
Data Management, Residential Building & Real Estate, Technology, Construction & Property, Other Technology, Apps, Applications, Software, Audio, Video, Internet, Mobile, Wireless, Other Construction & Property, Database, Pros, Maintenance, IPhone, Android, EDGAR, HVAC, Cobb, Heat, News, Video game, Online shopping, FrontDoor, Basic

Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home service plans, announced today that Frontdoor, the one-stop-app for all things home maintenance and repair, has reached over 225,000 downloads in just the four weeks since it launched on April 11.

Key Points: 
  • Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home service plans, announced today that Frontdoor, the one-stop-app for all things home maintenance and repair, has reached over 225,000 downloads in just the four weeks since it launched on April 11.
  • If you like the Basic experience, you can upgrade to Frontdoor Prime for additional benefits at just $99 a year.
  • The reports filed by Frontdoor pursuant to United States securities laws contain discussions of these risks and uncertainties.
  • Frontdoor assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Boulo Solutions Founder Shares Expertise at Second Annual Governor's Summit on Talent Retention and Work-based Learning

Retrieved on: 
Wednesday, May 3, 2023
Workforce, Boulo, Pros, Workplace, The Second Annual Report, Woman, Apprenticeship, Mother, Interface (computing), School, Cons, Learning, Caregiver, Management

BIRMINGHAM, Ala., May 3, 2023 /PRNewswire/ -- Boulo Solutions' founder and CEO Delphine Carter will share her front-line insights during a panel discussion on "The Pros and Cons of Working Remotely" at the Second Annual Governor's Summit on Talent Retention and Work-based Learning. Boulo Solutions is the recruiting industry's go-to resource connecting results-driven employers with a diverse talent pool—including women, mothers, and caregivers—looking for flexibility.

Key Points: 
  • BIRMINGHAM, Ala., May 3, 2023 /PRNewswire/ -- Boulo Solutions ' founder and CEO Delphine Carter will share her front-line insights during a panel discussion on "The Pros and Cons of Working Remotely" at the Second Annual Governor's Summit on Talent Retention and Work-based Learning .
  • Boulo Solutions is the recruiting industry's go-to resource connecting results-driven employers with a diverse talent pool—including women, mothers, and caregivers—looking for flexibility.
  • Boulo Solutions matches growth-mind employers with the talent they need to succeed.
  • The firm advocates for flexible work arrangements to reach "hidden talent" not found on traditional job boards or applying to company postings.

National Storage Affiliates Trust Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 1, 2023
Commercial Building & Real Estate, Construction & Property, REIT, Pressure, Intellectual property, Pros, Partnership, Housing, Share repurchase, Move It, OP, Jules Kroll, Retirement, NSA, NOI, NYSE, Video game, Security (finance)

National Storage Affiliates Trust ("NSA" or the "Company") (NYSE: NSA) today reported the Company’s first quarter 2023 results.

Key Points: 
  • National Storage Affiliates Trust ("NSA" or the "Company") (NYSE: NSA) today reported the Company’s first quarter 2023 results.
  • Reported net income of $40.4 million for the first quarter of 2023, a decrease of 9.8% compared to the first quarter of 2022.
  • Reported diluted earnings per share of $0.24 for the first quarter of 2023 compared to $0.24 for the first quarter of 2022.
  • Acquired 16 wholly-owned self storage properties for approximately $160.5 million during the first quarter of 2023.

Life Spine Releases Published Article on the Effect of Expandable Versus Static Lordotic Interbody Implants in Minimally Invasive Spine Surgery

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Surgery, Medical Devices, Health, Health Technology, Pain, PRO, Paper, JSS, Pros, Bleeding, ODI, Surgeon, Journal, VAS, Scoliosis and Spinal Disorders, Patient, Marketing, Medical imaging

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that the Company has published a new retrospective study examining the effect of expandable versus static interbody implants via the Journal of Spine Surgery (JSS).

Key Points: 
  • Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that the Company has published a new retrospective study examining the effect of expandable versus static interbody implants via the Journal of Spine Surgery (JSS).
  • The paper assessed the results of 100 patients who underwent transforaminal lumbar spinal fusion via minimally invasive surgery at L4-L5 or L5-S1.
  • “ProLift and our full line of Micro Invasive expandable products have received excellent feedback from surgeons.
  • This study validates that feedback and demonstrates significantly improved radiographic and PROs compared to the static cage.

The SPHERES Registry of Patients with NMOSD Reaches Enrollment Milestone of 200 Patients

Retrieved on: 
Wednesday, April 12, 2023
David Geffen School of Medicine at UCLA, Pros, Central nervous system, Therapy, Registry, Disability, NMO, MFIS, Spinal cord, Aes, Quality of life, Research, Brain, Biomarker, Experiment, Synergy, Disability studies, SPHERES, Patient, Physician, Collection, Cranial nerves, Neuromyelitis optica spectrum disorder, Diagnosis, UCLA, FDA, Disease, Autoimmunity, Safety, Inflammation, Pharmaceutical industry, Medicine, NMOSD

The SPHERES Registry has recruited 200 patients, across 23 sites in North America, supported by 72 physicians.

Key Points: 
  • The SPHERES Registry has recruited 200 patients, across 23 sites in North America, supported by 72 physicians.
  • Launched in early 2021, the SPHERES Registry serves as the first regulatory-grade and real-world study to advance the understanding of NMOSD.
  • To date, the SPHERES Registry has recruited 200 patients, across 23 sites in North America, supported by 72 physicians.
  • Today, advances in diagnosis, biomarkers, and newly FDA-approved treatment options offer patients with NMOSD the promise to lessen or prevent disability and enhance quality of life.

Leverage Novel Options in Oncology Clinical Trial Design to Reduce Burden For Patients and Sites, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, April 3, 2023
Flo, Knowledge, Shadow King, Science, Pros, PRO, Core, Doctor of Philosophy, Outline, Drug development, BBC, FDA, Medical device, Medical imaging

TORONTO, April 3, 2023 /PRNewswire-PRWeb/ -- The new FDA Patient Focused Drug Development (PFDD) Guidance Series and the Core Patient-Reported Outcomes Measures (PROMs) in Cancer Clinical Trials Guidance demonstrates the industry's commitment to optimizing clinical trial design, presenting the opportunity to minimize participant and site burden. Traditionally, oncology trials have been solely site-based, with lengthy, complex, and burdensome visits. They have also lacked a standard set of PRO domains and can have high levels of missing data.

Key Points: 
  • Attendees will gain insights into what domains should be measured in oncology trials to enable full realization of a treatment's value and facilitate comparison across studies.
  • The featured speaker will discuss the new concept of a modular approach – selecting only the relevant items from an existing instrument – for clinical trials.
  • Attendees will gain an understanding on how PROs can be captured outside clinical settings.
  • Join Flo Mowlem, PhD, Senior Director, eCOA Science & Solutions, Medable, for the live webinar on Monday, April 24, 2023, at 12pm EDT (9am PDT).

OTTO Motors' VP of Product Awarded as a Supply Chain Pro to Know for 2023

Retrieved on: 
Wednesday, March 22, 2023
Technology, Automotive, General Automotive, Engineering, Automotive Manufacturing, Manufacturing, Robotics, Supply Chain Management, Retail, Artificial Intelligence, Workforce, Demand, Knowledge, Ford, Gendron-Somua AMR 39, Supply, General Electric, Clearpath Robotics, Supply and demand, Safety, Food, Pros

Jay Judkowitz, VP of Product at OTTO Motors, a leading provider of autonomous mobile robots (AMRs), has been acknowledged as one of Supply & Demand Chain Executive’s Pros to Know for 2023.

Key Points: 
  • Jay Judkowitz, VP of Product at OTTO Motors, a leading provider of autonomous mobile robots (AMRs), has been acknowledged as one of Supply & Demand Chain Executive’s Pros to Know for 2023.
  • “This year’s list is filled with supply chain professionals whose achievements and success stories have helped move the needle in the supply chain.
  • They work toward helping heal the supply chain,” says Marina Mayer, Editor-in-Chief of Supply & Demand Chain Executive and Food Logistics.
  • “It’s truly an honor to be included in the 2023 list of Pros to Know,” said Jay Judkowitz, VP of Product at OTTO Motors.

Safety and Tolerability in Oncology Trials: Cardiac Imaging, ECG and the Role for Patient-Reported Outcomes, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, March 20, 2023
Blood pressure, Pros, US Foods, Depression, EVP, PRO, Food and Drug Administration, ECG, Doctor of Philosophy, QT interval, Outline, MD, Patient, Collection, Risk, FDA, Food, Safety, Medical device, Medical imaging, Clario Tech, Cardiology

TORONTO, March 20, 2023 /PRNewswire-PRWeb/ -- As clinical research in the oncology therapeutic area becomes increasingly complex, effectively capturing high-quality data across multiple endpoints becomes even more critical to a drug's success. Many oncologic agents have cardiac toxicities, including depression of left ventricular function, QTc prolongation and elevation of blood pressure.

Key Points: 
  • In this free webinar, learn about the unique aspects of assessing cardiac safety within an oncology development program.
  • Attendees will learn about the role of blood pressure monitoring in oncology studies and cardiac imaging to detect changes in cardiac function.
  • The speakers will discuss how patient-reported outcomes (PROs) for oncology clinical trials can help inform not only the risk but also the benefits seen by patients.
  • Register for this webinar to learn about the intersection of oncology drug development and cardiac safety, and how this new area is changing the landscape for early-phase clinical trials.